C4 Therapeutics, INC

C4 Therapeutics stockholders re-elected directors, ratified auditors, and approved an amendment to the 2020 Stock Option and Incentive Plan.

C4 Therapeutics announced positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, showing a 53% overall response rate in heavily pretreated relapsed/refractory multiple myeloma patients.

C4 Therapeutics, Inc. announced that Mark Mossler will depart as Chief Accounting Officer, with CFO Kendra R. Adams assuming the role.

C4 Therapeutics announced first-quarter 2026 financial results, highlighting progress in its cemsidomide multiple myeloma trials and a new collaboration with Roche focused on degrader-antibody conjugates.

C4 Therapeutics, Inc. has amended its bylaws to designate specific U.S. District Courts as the exclusive forums for securities-related litigation.

C4 Therapeutics and Roche have entered into a new research collaboration and license agreement to discover, develop, and commercialize degrader-antibody conjugates (DACs) for oncology.

C4 Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic collaborations.

C4 Therapeutics reported increased Q3 2025 net losses but bolstered its cash position with a $117 million underwritten offering, extending its operational runway to the end of 2028.

C4 Therapeutics reported increased net losses in Q2 2025, driven by higher research and development expenses, while maintaining a cash runway into mid-2027.

C4 Therapeutics' Q1 2025 results show increased collaboration revenue and ongoing clinical development, but significant operating losses persist.

C4 Therapeutics reports a net loss of $70.7 million for the nine months ended September 30, 2024, while highlighting progress in clinical trials and collaborations.

C4 Therapeutics reports a net loss of $46.1 million for the first half of 2024, with collaboration revenue increasing significantly compared to the same period last year.

C4 Therapeutics reports 2025 financial results, pipeline progress, and a significant capital raise, extending its operational runway through 2028.

C4 Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and highlights ongoing clinical trials and strategic collaborations.

C4 Therapeutics and Merck have entered into a licensing and collaboration agreement to develop degrader-antibody conjugates for an initial oncology target, with potential for expansion to additional targets.

Leonard Reyno, Chief Medical Officer of C4 Therapeutics, Inc., reported multiple transactions in common stock on July 10, 2026.

C4 Therapeutics, Inc. reports that Director Owen Hughes acquired 62,000 stock options with an exercise price of $4.25.

C4 Therapeutics Director Steven L. Hoerter acquired 62,000 stock options with an exercise price of $4.25.

C4 Therapeutics, Inc. reports that Director Utpal Koppikar was granted 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027.

C4 Therapeutics Director Kenneth Carl Anderson acquired 62,000 stock options with an exercise price of $4.25, vesting on June 24, 2027, or the next annual meeting.

C4 Therapeutics, Inc. reports that Director Ronald Harold Wilfred Cooper acquired 62,000 stock options with an exercise price of $4.25.

C4 Therapeutics announces its 2026 Annual Meeting of Stockholders, set for June 24, 2026, to elect directors, vote on executive compensation, ratify auditors, and approve a plan amendment.

C4 Therapeutics, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

C4 Therapeutics is holding its 2025 Annual Meeting of Stockholders to elect directors, approve executive compensation, ratify the appointment of KPMG LLP, and increase the number of authorized shares of common stock.

C4 Therapeutics has filed a definitive proxy statement with the SEC, indicating preparations for an upcoming shareholder meeting.

C4 Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 20, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.

BlackRock, Inc. has reported a beneficial ownership of 6.9% of C4 Therapeutics, Inc.'s common stock as of June 30, 2026.

Squadron Master Fund LP, along with affiliated entities and individuals, has disclosed a beneficial ownership of 5,550,000 shares, representing 5.0% of the outstanding common stock of C4 Therapeutics, Inc.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have disclosed a beneficial ownership of 0.2% in C4 Therapeutics, Inc. common stock.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of C4 Therapeutics, Inc. common stock, primarily through warrants.

Wasatch Advisors LP has filed an amendment disclosing a reduction in its beneficial ownership of C4 Therapeutics Inc to 4.7%.

Lynx1 Capital Management LP and Weston Nichols have disclosed a 7.3% beneficial ownership stake in C4 Therapeutics, holding 7,098,133 shares.